SAMR discloses deal abandonments in pharma, natural-monopoly sectors in 2024
China’s top merger-control regulator revealed that its deal reviews in 2024 led to deal abandonments in key sectors such as pharmaceuticals and natural monopolies after it identified competition concerns. In its 2024...To view the full article, register now.
Already a subscriber? Click here to view full article